The researchers found 91% of patients in one group with a specific mutation remained disease-free five years after surgery, meaning patients in this group may potentially avoid unnecessary treatment. Meanwhile, the percentage of patients in a different mutation group who remained disease-free at five years was much lower, at 51%. This group of patients needed more aggressive treatment.
The results of this research means that tumour DNA sequencing may provide a more effective way to predict a patient’s risk of their kidney cancer coming back. This could, in the future, lead to more personalised treatment for kidney cancer.